BioSenic to extend US patent for sepsis ATO treatment

BioSenic and its subsidiary, Medsenic, have recently submitted a continuation patent application to the United States Patent & Trademark Office (USPTO). This move aims to extend the protection of their use of arsenic trioxide (ATO) in preventing and treating sepsis syndrome. The application, identified as US 18/763,376, specifically seeks to safeguard the usage of Medsenic's ATO platform in combating the cytokine storm linked to systemic infections.

The patent protection being sought encompasses two main areas: immune and autoimmune-related diseases, and oncology. Within the realm of immune and autoimmune-related diseases, the focus is on conditions such as chronic graft-versus-host disease, systemic sclerosis, and systemic lupus erythematosus. In the field of oncology, ATO has shown significant promise, especially in patients suffering from acute promyelocytic leukemia.

This application could potentially lead to further divisional filings, particularly at the European Patent Office, thereby expanding the scope of protection internationally. The growing patent portfolio supports Medsenic/BioSenic’s global clinical trials aimed at addressing diseases that currently lack effective treatments.

The company is also working towards obtaining market access approvals for various formulations. These formulations are designed to refine the original properties of arsenic salts, either used alone or in combination with other substances. BioSenic is optimistic about the future availability of both intravenous and oral formulations that combine arsenic with copper. This combination is seen as a way to capitalize on their preclinical successes.

Medsenic and BioSenic plan to persist with clinical development efforts, focusing on formulations that integrate arsenic with new active ingredients like metal ions. These new combinations are expected to enhance the efficacy of the products while minimizing side effects.

François Rieger, the chairman and CEO of BioSenic, expressed enthusiasm about the ongoing efforts to broaden the scope of indications and intellectual property. He believes that the unique properties of arsenic salts hold significant potential for advancing both clinical and commercial development. According to Rieger, arsenic salts exhibit critical and novel biological properties that could lead to new treatment methods for immune system diseases and certain cancers, which currently have no effective medical treatments.

Rieger highlighted that pharmacological formulations containing arsenic salts often help organisms return to normal cellular and organ functions, thereby restoring homeostasis. This restoration could provide new therapeutic avenues for treating a variety of conditions.